Tesamorelin

Chemical formula: C₂₂₁H₃₆₆N₇₂O₆₇S Molecular mass: 5,005.76 g/mol PubChem compound: 56928011

Therapeutic indications

Tesamorelin is indicated for:

Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy

Population group: only adults (18 - 65 years old)

Tesamorelin is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

Limitations of use:

Long-term cardiovascular safety of tesamorelin has not been established. Consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue.
Tesamorelin is not indicated for weight loss management as it has a weight neutral effect.
There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking tesamorelin.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2 mg once daily

Contraindications

Tesamorelin is contraindicated in the following cases:

Pregnancy

Active malignancy

Malignant tumour

Disruption of the hypothalamic-pituitary axis

at least one of

Hypophysectomy
Hypopituitarism
Hypothalamic-pituitary-adrenal axis dysfunction

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.